Cicletanine
 | |
| Systematic (IUPAC) name | |
|---|---|
| 3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Oral | |
| Pharmacokinetic data | |
| Protein binding | 97.3% |
| Half-life | 7.9 h |
| Identifiers | |
| 89943-82-8 | |
| C03BX03 | |
| PubChem | CID 54910 |
| ChemSpider |
49583  |
| UNII |
CHG7QC509W |
| KEGG |
D03487 |
| ChEMBL |
CHEMBL191886 |
| Chemical data | |
| Formula | C14H12ClNO2 |
| 261.703 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Cicletanine is a furopyridine low-ceiling diuretic drug, usually used in the treatment of hypertension.[1] The drug is manufactured by Ipsen and marketed by Recordati (in France) under the trade name Tenstaten.
It appears to be more potent in salt-sensitive hypertension.[2]
Mechanism
It can inhibit protein kinase C.[3]
References
- ↑ Jean Sassard (1992). Genetic Hypertension. John Libbey Eurotext. ISBN 978-0-86196-313-3.
- ↑ Bagrov AY; Dmitrieva RI; Dorofeeva NA et al. (February 2000). "Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism". J. Hypertens. 18 (2): 209–15. doi:10.1097/00004872-200018020-00012. PMID 10694190.
- ↑ Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY (March 2003). "Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension". Hypertension 41 (3): 505–11. doi:10.1161/01.HYP.0000053446.43894.9F. PMID 12623951.
External links
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||